Best Medications for OCD
SSRIs (selective serotonin reuptake inhibitors) are the first-line pharmacological treatment for OCD, with all SSRIs showing similar efficacy—choose based on side effect profile, drug interactions, comorbidities, cost, and availability. 1
Why SSRIs Are First-Line
The evidence strongly supports SSRIs over clomipramine despite older meta-analyses suggesting clomipramine superiority. SSRIs have a significantly better safety and tolerability profile compared to clomipramine, making them superior for long-term treatment 1. Head-to-head trials show equivalent efficacy between clomipramine and SSRIs, and the apparent advantage of clomipramine in meta-analyses is likely due to those trials being conducted earlier on less treatment-resistant patients 1.
Dosing Strategy
- Use higher doses than for depression or other anxiety disorders—higher SSRI doses are associated with greater efficacy in OCD 1
- Trial duration: 8-12 weeks minimum to determine efficacy 1
- However, you should see some improvement within 2-4 weeks; early response predicts ultimate treatment success 1
- Maintenance: Continue for 12-24 months minimum after remission, often longer due to high relapse risk 1
Selecting Among SSRIs
All SSRIs show similar effect sizes 1, so your choice should be driven by:
- Side effect profiles (e.g., sexual dysfunction, GI symptoms, activation)
- Drug interactions with other medications
- Comorbid medical conditions
- Cost and availability
- Past treatment response 1
Common pitfall: Starting at antidepressant doses rather than the higher doses needed for OCD, or discontinuing too early (before 8-12 weeks).
When First-Line Treatment Fails
Approximately 50% of patients fail to fully respond to first-line treatment 1. The most evidence-based augmentation strategy is adding low-dose risperidone or aripiprazole 2. Other validated options include:
- Switching to a different SSRI
- Increasing SSRI dose above maximum recommended
- Adding clomipramine to SSRI (superior to adding quetiapine in the only head-to-head trial) 1—but this carries serious risks including seizures, arrhythmias, and serotonin syndrome due to drug-drug interactions 1
- Augmentation with CBT (larger effect sizes than antipsychotic augmentation) 1
Critical caveat on antipsychotic augmentation: While commonly used, the effect size is modest—only one-third of SSRI-resistant patients show clinically meaningful response 1. Monitor closely for metabolic side effects and weight gain 1.
What NOT to Use
Based on recent high-quality evidence 2:
- Antipsychotic monotherapy (ineffective)
- Ketamine augmentation (potentially harmful)
- Lamotrigine augmentation (ineffective)
- N-acetylcysteine augmentation (ineffective despite earlier promise)
The 2023 Brazilian guidelines 2 specifically classify these as ineffective or potentially harmful based on updated systematic review.